Healthcare
KKR set for $576m windfall from Gland Pharma exit
KKR will exit India-based Gland Pharma as Shanghai Fosun Pharmaceutical acquires a majority stake in the business for up to $1.26 billion. KKR’s share of the proceeds will be $576.3 million, more than twice what it invested in Gland in 2014.
Australia's Brandon Capital expands into New Zealand
Australian life sciences-focused VC firm Brandon Capital has expanded the mandate of its third Medical Research Commercialization Fund (MRCF) to include New Zealand.
KKR to exit GenesisCare as China Resources, Macquarie buy control
KKR will sell its 45% stake in Australia-based healthcare provider GenesisCare as China Resources Group and Macquarie Capital agreed to buy a majority interest in the business.
EQT exits Singapore's Econ Healthcare
EQT Partners has agreed to sell its 49% stake in Singapore’s Econ Healthcare to the company’s founder Chu-Poh Ong ahead of a regional expansion initiative.
Diamedica gets $4m for China push
Hermed Capital Healthcare Fund, a PE vehicle managed by Shanghai Fosun Pharmaceutical Group and Korea’s SK Group, has committed $4 million to a China expansion drive by US-based Diamedica.
TPG buys control of India maternity hospital operator
TPG Capital’s growth investment arm has paid $33 million for a significant majority stake in Rhea Healthcare, which operates a network of mother and child care centers in India under the Motherhood brand.
Suning, Tencent invest in China VC-backed cosmetic surgery app
Gengmei, a Chinese cosmetic surgery social networking app backed by several VC investors, has raised an undisclosed amount of Series C funding from Chinese companies Suning Commerce Group and Tencent Holdings.
Creador invests $18m in India's Corona Remedies
Creador has committed INR1.2 billion ($17.6 million) to India-based pharmaceutical developer Corona Remedies.
IDG Capital Partners closes $1b China VC fund
IDG Capital Partners has closed its latest China-focused venture capital fund at $1 billion, in partnership with Silicon Valley-based Breyer Capital.
Carlyle to exit China's Concord Medical via founder-led privatization
The Carlyle Group is set to make a full exit from Concord Medical Services, a US-listed Chinese radiotherapy and diagnostic imaging center operator, in a take-private transaction initiated by the company’s chairman and CEO.
Advent makes two investments in Australia
Australia’s Advent Private Capital has made investments in two separate domestic social services companies on the back of two exits.
Singapore's Aslan Pharma raises $23m pre-IPO round
Singapore-based biotech company Aslan Pharmaceuticals has raised $23 million in a pre-IPO financing round that attracted participation from a range of new investors, including a number of Taiwanese groups.
Cross-border VC: Changes in the wind
US-China cross border investment continues to present exciting opportunities for venture capital firms targeting technology start-ups, but investors must keep up with the pace of the market’s transformation
Quadria buys into India's Concord Biotech
Quadria Capital has led a consortium including US-based investment firms Rising Tide and Neuberger Berman to take a stake in India’s Concord Biotech.
WuXi, Boyu, Oriza commit $150m to China's CStone
WuXi Healthcare Ventures, Oriza Seed Venture Capital, and Boyu Capital have committed $150 million in Series A funding to Chinese bio-pharmaceutical developer CStone Pharmaceuticals.
Mandala buys India's EFRAC for $10m
Mandala Capital, a South-Asia focused PE firm that invests in the agricultural sector, has paid $10 million for a 51% stake in Indian testing laboratory EFRAC.
Navis seals healthcare deals in Indonesia, Vietnam
Navis Capital Partners has closed two Southeast Asia healthcare deals, with agreements to buy Indonesia-based medical devices distributor Tawada Healthcare and Vietnam’s Hanoi French Hospital.
Carlyle re-lists Japan healthcare staffing business
The Carlyle Group has re-listed Solasto Corporation on the Tokyo Stock Exchange, four and a half years after privatizing the medical staffing business, which was previously known as NIC Corp.
China Everbright's mezzanine fund backs Neusoft Medical
China Everbright has invested an undisclosed amount in Chinese healthcare conglomerate Neusoft Holdings through its renminbi-denominated mezzanine fund.
GPs set for partial exits in India's Aster DM Healthcare IPO
Indian hospital chain Aster DM Healthcare has filed for an IPO, seeking to raise at least INR6.1 billion ($89 million) and providing partial exits for its PE backers Olympus Capital Asia and India Value Fund Advisors (IVFA).
Carlyle hires ex-Johnson & Johnson chair to advise Asia buyout
The Carlyle Group has hired Jesse Wu, the former chairman of Johnson & Johnson China, as a senior advisor to the firm’s Asia buyout team.
OrbiMed, Chinese strategic to buy Canadian healthcare player
OrbiMed will consolidate its control of Canada-listed clinical equipment producer Response Biomedical in an C$11.1 million ($8.6 million) take-private deal including participation by Shanghai Runda Medical Technology.
HighLight Capital leads $7.6m round for TCM play
Chinese healthcare-focused GP HighLight Capital has led a RMB50 million ($7.6 million) Series B round for Jun He Tang, a traditional Chinese medicine (TCM) business, followed by existing investor Qiming Venture Partners.
Shenzhen Hepalink commits $60m to TPG biotech fund
Chinese drug maker Shenzhen Hepalink Pharmaceutical has agreed to commit $60 million to TPG Capital’s latest biotech fund.